Navigation Links
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
Date:11/19/2007

controlled satisfactorily by diet and exercise alone. Prandin(R) is also indicated for combination therapy use (with metformin or thiazolidinediones) for patients whose hyperglycemia cannot be controlled by diet and exercise plus monotherapy with any of the following agents: metformin, sulfonylureas, repaglinide, or thiazolidinediones.

Prandin(R) is contraindicated in patients with diabetic ketoacidosis (with or without coma, type 1 diabetes, or known hypersensitivity to the drug or its inactive ingredients. Prandin(R) is not indicated for use in combination with NPH insulin. All oral blood glucose-lowering drugs, including Prandin(R), are capable of producing hypoglycemia. Full prescribing information is available at novonordisk-us.com.

Financial terms of the agreement are not being disclosed.

About Novo Nordisk Inc.

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.

About Sciele Pharma, Inc.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of bra
'/>"/>

SOURCE Novo Nordisk Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
2. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... that Pierre Noel, M.D., Professor of Medicine, Mayo ... the Company’s Board of Directors. , ... are extremely fortunate to have Dr. Noel, a ... leading healthcare organization, join Entegrion’s Board. His expertise ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Thornton Cleveleys (UK) (PRWEB) March 05, 2015 ... Enhanced implantable polymer have received the CE mark (European) ... within the European Free Trade Association (EFTA) and the ... CE mark has now been granted to implants supplied ... degenerative disc spinal conditions. , Osimplant's Cervical Expandable ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3Latest Clinical Information On Bioterrorism Threats 2
... risk of variant Creutzfeldt-Jakob Disease from plasma product completed ... - Scale-up phase ... to supply prion removal affinity ... CAMBRIDGE, United Kingdom, Jan. 23 /PRNewswire-FirstCall/,- ProMetic Life Sciences Inc. ...
... Institute and Rice University have created the darkest material ... thin coating comprised of low-density arrays of loosely vertically-aligned ... and one day could be used to boost the ... and other devices. The researchers who developed the material ...
... VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... host a conference call discussing its,financial results for the fourth quarter ... Thursday, February 14, 2008 at 11:00 AM ET ... Central), Dial information is as follows: ...
Cached Biology Technology:ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use 2ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use 3ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use 4ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use 5Researchers develop darkest manmade material 2Researchers develop darkest manmade material 3Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast 2
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)... Jan. 30, 2015  It is gratifying to see ... potential for genomic science as a means to better ... and treatment.  I was honored to participate in today,s ... medicine program. Since the 1980s my ... genomics—from the first sequenced genome of a free living ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... revealed how the inhaled form of anthrax paralyzes the ... site of infection. , Anthrax killed five people in ... through the mail. The UF findings, published last week ... for anthrax victims. , The disease causes flu-like ...
... Tropical plants may be more adaptable than commonly thought to ... research shows. , A University of Florida scientist and other ... to acclimate to big changes in rainfall in at least ... rely on one form of the vital nutrient nitrogen in ...
... land area and number of species crystallized into a ... thought of as biological destinations where species from large ... in geographic seclusion. , Since islands have many ... logical that continents were rich sources from which islands ...
Cached Biology News:Anthrax paralyzes immune cells with lethal toxin, UF research shows 2Anthrax paralyzes immune cells with lethal toxin, UF research shows 3Scientists: As rainfall changes, tropical plants may acclimate 2Invasion of the island bats 2
SHEEP ANTI FLECAINIDE...
... in refrigerators, freezers, or liquid nitrogen. Conveniently sized to ... color coding to project, user, lab, etc. Holes in ... air circulation. Supplied with 9 x 9 (12.7 mm ... dimensions: 13 x 13 x 5.1 cm H (5 ...
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Biology Products: